Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Byrna Technologies Inc (BYRN) vs Crispr Therapeutics AG (CRSP) Price & Performance

Byrna Technologies IncTrade
Crispr Therapeutics AGTrade

Price performance (Past 24H)

Key statistics

Byrna Technologies Inc vs Crispr Therapeutics AG — how do they compare? Byrna Technologies Inc trades at $4.32 (market cap $106.74M), while Crispr Therapeutics AG trades at $53.84 (market cap $5.23B). The key difference: Crispr Therapeutics AG is far larger — about 49× Byrna Technologies Inc's market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, Byrna Technologies Inc nearer its low. Which is the better fit depends on your goals.

BYRNCRSP
Market Cap
$106.74M$5.23B
Sector
TechnologyHealth
52-Week High
$27.63$76.78
52-Week Low
$3.18$44.34
Enterprise Value
$98.35M$3.65B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Byrna Technologies Inc

BYRN trades at $4.34, down 10.52% in 24 hours, with a mixed technical outlook showing bullish moving averages but neutral oscillators. The company reported a net loss in 2026 with a negative net income margin of -3.39%, though it maintains a strong gross profit margin of 52.51%. Recent leadership appointments aim to bolster marketing and retail expansion, while Q2 2026 earnings missed estimates with a loss of $0.44 per share.

The outlook is challenged by recent earnings misses and declining revenue, but analyst consensus remains bullish with 71% buy ratings. Key risks include execution in sales turnaround and competitive pressures. Upside depends on successful implementation of new growth initiatives and improved financial performance in upcoming quarters.

Crispr Therapeutics AG

CRISPR Therapeutics (CRSP) trades at $53.83, up 0.6% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a Q2 2026 EPS beat with a loss of $0.94 versus an expected $1.19 loss, driven by surging CASGEVY sales. However, financials show deep losses, with a net income margin of -4,101.26% in 2025 and negative operating cash flow, though financing activities provided liquidity.

The outlook is mixed: strong analyst consensus (57.9% buy ratings) and a $82.67 price target reflect optimism around CASGEVY growth and pipeline catalysts, but high valuation (P/S of 466.05) and persistent cash burn pose significant risks. Investment appeal hinges on successful clinical advancements and path to profitability.

Returns comparison

Trailing returns across standard periods

About Byrna Technologies Inc

Byrna Technologies specializes in less-lethal personal security devices. It develops and manufactures innovative handheld launchers and projectiles designed for self-defense, law enforcement, and private security use.

Read more on BYRN

About Crispr Therapeutics AG

CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.

Read more on CRSP